Lower use of antiosteoporosis medication seen for men vs. women; men had higher rates of all-cause mortality<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, July 18, 2023 (HealthDay News) — Although age- and sex-standardized hip fracture incidence rates have decreased in most regions, the number of hip fractures is projected to nearly double by 2050, according to a study recently published in the Journal of Bone and Mineral Research<\/em>.<\/p>\n Chor-Wing Sing, Ph.D., from the University of Hong Kong, and colleagues used data from 19 countries and regions to identify patients aged 50 years and older hospitalized with a hip fracture from 2005 to 2018 to examine the incidence of hip fracture, postfracture treatment, and all-cause mortality. Data were included for 4,115,046 hip fractures.<\/p>\n The researchers observed variation in the reported age- and sex-standardized incidence rates of hip fractures, from 95.1 to 315.9 per 100,000 population in Brazil and Denmark, respectively. During the study period, incidence rates decreased in most countries; however, from 2018 to 2050, the estimated total annual number of hip fractures was projected to nearly double. Within one year following a hip fracture, postfracture treatment varied from 11.5 to 50.3 percent in Germany and the United Kingdom, respectively, and all-cause mortality rates varied from 14.4 to 28.3 percent in Singapore and the United Kingdom, respectively. Compared with women, men had lower use of antiosteoporosis medication, higher rates of all-cause mortality, and a larger increase in the projected number of hip fractures by 2050.<\/p>\n “The findings of this important study highlight the urgent need for improved strategies in hip fracture prevention and care,” a coauthor said in a statement. “This should be seen as both a warning and a call to action for health care systems worldwide.”<\/p>\n Several authors and their institutions received financial support from Amgen, which funded the study.<\/p>\n